Tharimmune Total Assets from 2010 to 2024
| THAR Stock | 2.08 0.18 7.96% |
Total Assets | First Reported 2010-12-31 | Previous Quarter 10.9 M | Current Value 11.5 M | Quarterly Volatility 4.1 M |
Check Tharimmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tharimmune's main balance sheet or income statement drivers, such as Net Interest Income of 142.9 K, Interest Expense of 15.7 K or Selling General Administrative of 6.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0758. Tharimmune financial statements analysis is a perfect complement when working with Tharimmune Valuation or Volatility modules.
Tharimmune | Total Assets |
Latest Tharimmune's Total Assets Growth Pattern
Below is the plot of the Total Assets of Tharimmune over the last few years. Total assets refers to the total amount of Tharimmune assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Tharimmune books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Tharimmune's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tharimmune's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 10.95 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Tharimmune Total Assets Regression Statistics
| Arithmetic Mean | 2,030,268 | |
| Geometric Mean | 166,045 | |
| Coefficient Of Variation | 201.94 | |
| Mean Deviation | 3,071,724 | |
| Median | 40,881 | |
| Standard Deviation | 4,099,887 | |
| Sample Variance | 16.8T | |
| Range | 11.5M | |
| R-Value | 0.71 | |
| Mean Square Error | 9T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | 649,738 | |
| Total Sum of Squares | 235.3T |
Tharimmune Total Assets History
Other Fundumenentals of Tharimmune
Tharimmune Total Assets component correlations
Click cells to compare fundamentals
About Tharimmune Financial Statements
Tharimmune shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Tharimmune investors may analyze each financial statement separately, they are all interrelated. The changes in Tharimmune's assets and liabilities, for example, are also reflected in the revenues and expenses on on Tharimmune's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 10.9 M | 11.5 M |
Pair Trading with Tharimmune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tharimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tharimmune will appreciate offsetting losses from the drop in the long position's value.Moving against Tharimmune Stock
| 0.62 | HCM | HUTCHMED DRC | PairCorr |
| 0.6 | GANX | Gain Therapeutics | PairCorr |
| 0.59 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.56 | BCTXW | BriaCell Therapeutics | PairCorr |
| 0.48 | EBS | Emergent Biosolutions | PairCorr |
The ability to find closely correlated positions to Tharimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tharimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tharimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tharimmune to buy it.
The correlation of Tharimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tharimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tharimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tharimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tharimmune Stock Analysis
When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.